Angiogenesis and inflammation are central processes through which the tumor microenvironment influences tumor growth. We have demonstrated recently that peroxisome proliferatoractivated receptor (PPAR)␣ deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of PPAR␣ would promote tumor growth. Surprisingly, the PPAR␣ agonist fenofibrate potently suppressed primary tumor growth in mice. This effect was not mediated by cancer-cell-autonomous antiproliferative mechanisms but by the inhibition of angiogenesis and inflammation in the host tissue. Although PPAR␣-deficient tumors were still susceptible to fenofibrate, absence of PPAR␣ in the host animal abrogated the potent antitumor effect of fenofibrate. In addition, fenofibrate suppressed endothelial cell proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovascularization. Thus, both genetic abrogation of PPAR␣ as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways. These findings reveal the potential utility of the well tolerated PPAR␣ agonists beyond their use as lipid-lowering drugs in anticancer therapy. Our results provide a mechanistic rationale for evaluating the clinical benefits of PPAR␣ agonists in cancer treatment, alone and in combination with other therapies. stroma ͉ inflammation ͉ fibrates ͉ microenvironment P eroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors comprising three isoforms, PPAR␣, PPAR␦, and PPAR␥, which act as ligand-activated transcriptional factors. PPARs play key roles in energy homeostasis by modulating glucose and lipid metabolism and transport (1). PPAR␣ is also critical in inflammation (2) and is the molecular target of the fibrate class of drugs, such as fenofibrate, which act as agonistic ligands of PPAR␣.
Angiogenesis and inflammation are central processes through which the tumor microenvironment influences tumor growth. We have demonstrated recently that peroxisome proliferatoractivated receptor (PPAR)␣ deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of PPAR␣ would promote tumor growth. Surprisingly, the PPAR␣ agonist fenofibrate potently suppressed primary tumor growth in mice. This effect was not mediated by cancer-cell-autonomous antiproliferative mechanisms but by the inhibition of angiogenesis and inflammation in the host tissue. Although PPAR␣-deficient tumors were still susceptible to fenofibrate, absence of PPAR␣ in the host animal abrogated the potent antitumor effect of fenofibrate. In addition, fenofibrate suppressed endothelial cell proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovascularization. Thus, both genetic abrogation of PPAR␣ as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways. These findings reveal the potential utility of the well tolerated PPAR␣ agonists beyond their use as lipid-lowering drugs in anticancer therapy. Our results provide a mechanistic rationale for evaluating the clinical benefits of PPAR␣ agonists in cancer treatment, alone and in combination with other therapies. stroma ͉ inflammation ͉ fibrates ͉ microenvironment P eroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors comprising three isoforms, PPAR␣, PPAR␦, and PPAR␥, which act as ligand-activated transcriptional factors. PPARs play key roles in energy homeostasis by modulating glucose and lipid metabolism and transport (1) . PPAR␣ is also critical in inflammation (2) and is the molecular target of the fibrate class of drugs, such as fenofibrate, which act as agonistic ligands of PPAR␣.
Long-term administration of certain PPAR␣ agonists (clofibrate and WY14643) induces hepatocarcinogenesis in rodents but not in humans (3) . Consequently, PPAR␣ has not been established as a molecular target for cancer therapy by its agonistic ligands. In contrast, PPAR␥ and PPAR␦ agonists have been extensively studied to evaluate their anticancer effects because of their antiproliferative, proapoptotic, antiapoptotic, and differentiation-promoting activity (4) . However, recent studies have revealed the expression of PPAR␣ in tumor cells (5, 6) , and PPAR␣ ligands suppress the growth of several cancer lines, including colon, breast, endometrial and skin, in vitro (7) (8) (9) (10) . PPAR␣ ligands also suppress the metastatic potential of melanoma cells in vitro and in vivo (11, 12) . Furthermore, PPAR␣ ligands decrease tumor development in murine colon carcinogenesis (7) . Clofibric acid inhibits the growth of human ovarian cancer in mice (13) . Most recently, the PPAR␣ agonist WY14643 suppresses tumorigenesis in a PPAR␣-dependent manner (14) .
Together, these data suggest that PPAR␣ ligands may have an important role as antitumor agents, although the mechanism remains elusive. PPAR␣ is expressed not only in tumor cells but also in endothelial and inflammatory cells (15, 16) . Also, PPAR␣ ligands can inhibit endothelial cell proliferation and migration and induce endothelial cell apoptosis in vitro (17) (18) (19) . In addition, fenofibrate reduces adventitial angiogenesis and inflammation in a porcine model (20) and decreases VEGF levels in patients with hyperlipidemia and atherosclerosis (21) . However, the relative role of PPAR␣ in tumor angiogenesis and tumor inflammation has not been studied.
Here, we report that PPAR␣ is expressed both in tumor cells and in tumor endothelium. We show that PPAR␣ ligands have potent antitumor and antiangiogenic effects, both in vitro and in vivo. Our data demonstrate that PPAR␣ expression in the host rather than in the tumor cell is critical for the antitumor, antiangiogenic, and antiinflammatory activity of PPAR␣ ligands. This extends the repertoire of potential targets of PPAR␣ ligands beyond cell-autonomous mechanisms of cancer. Our findings may be of clinical relevance because PPAR␣ ligands such as fenofibrate are orally administered, Food and Drug Administration-approved drugs widely used for the treatment of hyperlipidemia with minimal side effects.
Results

PPAR␣ Is Expressed in Tumor Cells in Vitro and in Tumor Endothelium
in Vivo. We first screened 19 human tumor cell lines for PPAR␣ expression in vitro. In Western blot analysis of cell cultures, we found that all tumor cell lines examined expressed the PPAR␣ protein, although at varying levels (Fig. 1a) . We obtained similar results in murine tumor cell lines, albeit at a lower intensity. The signal could be specifically neutralized with a blocking peptide (Fig. 1b) . Expression patterns in tumor tissues were assessed by immunofluorescent double staining for PPAR␣ and the endothelial marker CD31. PPAR␣ staining was examined in s.c. implanted human pancreatic cancer cells (BxPC3) grown in mice (Fig. 1c) , as well as in clinical specimens from human prostate carcinoma (Fig. 1d) . We found expression of PPAR␣ in the tumor cells as well as in human and murine endothelial cells of microvessels ( Fig. 1 c and d ).
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PPAR␣ Ligands Have Direct Antitumor and Antiendothelial Effects in
Vitro. Given the presence of PPAR␣ in multiple cell types, we next compared the effect of PPAR␣ ligands for their ability to inhibit the proliferation of tumor cells, endothelial cells, and fibroblasts. PPAR␣ ligands examined included fenofibrate, gemfibrozil, bezafibrate, WY14643, and 5,8,11,14-eicosatetraynoic acid (ETYA). Fenofibrate was most potent in suppressing the proliferation of all tumor cell lines tested, including melanoma (B16-F10), breast carcinoma (MDA436), and Lewis lung carcinoma (LLC) cells [ Fig. 2a and supporting information (SI) Fig.  6 ]. Fenofibrate, WY14643, and ETYA inhibited FGF2-induced proliferation of bovine capillary endothelial cells up to 95% after 3 days (Fig. 2b) . In addition, fenofibrate inhibited VEGFstimulated proliferation of human umbilical vein endothelial cells (HUVECs) (data not shown). In contrast to tumor and endothelial cells, PPAR␣ ligands failed to inhibit the proliferation of fibroblasts (foreskin) at doses Ͻ50 M (SI Fig. 7a ). Moreover, fenofibrate and WY14643 inhibited VEGFstimulated endothelial cell migration (SI Fig. 7 b and c) . These doses used here are clinically relevant because fibrates in humans readily achieve similar serum levels (22) .
To determine whether PPAR␣ ligands could inhibit angiogenesis by down-regulating tumor-secreted growth factors and/or up-regulating endogenous angiogenesis inhibitors, such as thrombospondin (TSP)-1, we measured VEGF, FGF2, and TSP-1 levels in tumor-conditioned media. Fenofibrate and WY14643 at 50 M inhibited VEGF secretion in glioblastoma (U87) cells by 43-55% and in LLC by 51-58% (SI Fig. 8 a and  b) . Both PPAR␣ ligands also inhibited FGF2 secretion in K1000 cells (a tumor cell line that expresses and secretes high levels of FGF2) by up to 70% (SI Fig. 8c ). In addition, fenofibrate also increased the expression of TSP-1 by 3-to 4-fold in HT-1080 fibrosarcoma and in LLC tumor cells (SI Fig. 8d and data not shown). Therefore, in addition to their direct antitumor and antiendothelial effects, PPAR␣ ligands may suppress angiogenesis indirectly by inhibiting tumor cell production of VEGF and FGF2 and by increasing TSP-1.
PPAR␣ Ligands Inhibit FGF2-Induced Corneal Neovascularization. To determine the optimal antiangiogenic doses of PPAR␣ ligands for daily administration in mice, we performed the cornea angiogenesis assay in the presence of five different PPAR␣ ligands (Fig. 2 c-h ). Systemic oral administration of these inhibition; ETYA (50 mg/kg per day), 42% inhibition; bezafibrate (400 mg/kg per day), 44% inhibition; and gemfibrozil (400 mg/kg per day), 22% inhibition. Inhibition was determined on day 6 by the following formula: pellet distance ϫ 0.2 ϫ neovessel length ϫ clock hours of neovessels. (n ϭ 6 eyes per group; the experiment was performed three times.)
PPAR␣ agonists significantly inhibited FGF2-induced corneal angiogenesis by Ͼ50% compared with the control (depending on the compound) (Fig. 2i ).
Systemic Therapy with PPAR␣ Ligands Inhibits Primary Tumor Growth.
To determine whether these antiangiogenic effects of PPAR␣ agonists translate to suppression of primary tumors, we treated established s.c. tumors of 100 mm 3 with PPAR␣ agonists. Oral fenofibrate (200 mg/kg per day) inhibited B16-F10 melanoma, LLC, glioblastoma (U87), and fibrosarcoma (HT1080) tumor growth by 61%, 58%, 72%, and 66%, respectively, and was more potent than other fibrates, such as bezafibrate and gemfibrozil (Fig. 3 a-d ). Systemic therapy with WY14643 also inhibited the growth of B16-F10 melanoma, LLC, and fibrosarcoma (HT1080) by 66%, 65%, and 71%, respectively (Fig. 3 a, b, and  d) . No weight loss or evidence of other drug-related toxicity was observed. Furthermore, no signs of hepatocarcinogenesis were observed in mice treated with PPAR␣ ligands.
Given the in vitro evidence for antiangiogenic activity and the known inflammation-modulatory role of PPAR␣ stimulation, we analyzed the tissues of PPAR␣ ligand treated B16-F10 tumors for antiangiogenic and antiinflammatory effects. Fenofibrate and WY14643 treatment reduced vessel density by 83% and 81%, respectively, relative to that in the control tumors ( Fig. 3e and SI  Fig. 9 ), consistent with the decrease of microvessel density in murine tumor models after treatment with PPAR␣ ligands (13, 14) .
In addition, fenofibrate and WY14643 treated tumors exhibited a dramatic reduction in leukocytes by 62% and 67% (CD45) (Fig. 3f  and SI Fig. 9 ). Treatment with PPAR␣ ligands also led to an increase of TSP-1 in B16-F10 tumors (Fig. 3g) . In contrast, the enzyme COX-2, which is an important mediator of inflammation and also regulates endothelial cell activity (23), was suppressed in both fenofibrate-and WY14643-treated B16-F10 tumors (Fig. 3g ).
Antiangiogenic and Antitumor Effects of PPAR␣ Ligands Are Specific
to the Activation of PPAR␣. To demonstrate the activation of PPAR␣ in endothelial cells, we measured the kinetics of induction of the medium chain acyl-dehydrogenase (MCAD), a target gene of PPAR␣, in HUVECs. After 12-24 h of fenofibrate treatment (25 M), MCAD levels increased in a dose-dependent manner, indicating PPAR␣ activation (data not shown). Furthermore, PPAR␣ ligand-mediated inhibition of FGF2-induced proliferation of bovine capillary endothelial cells was reduced by 90% with the PPAR␣ antagonist MK886 (10 M; P Ͻ 0.001) (Fig. 4a) . In addition, PPAR␣ ligands inhibited corneal neovascularization in PPAR␣ WT (52%) but not in PPAR␣ KO mice (Fig. 4b) . These findings indicate that the antiangiogenic activity of PPAR␣ ligands specifically depends on activation of PPAR␣.
To confirm that the suppression of tumor cell proliferation by PPAR␣ agonists was specific to PPAR␣ activation, we examined whether fenofibrate could inhibit the proliferation of PPAR␣-deficient tumor cells. Therefore, we created a PPAR␣-negative tumor cell line by transforming mouse embryonic fibroblasts (MEFs) derived from PPAR␣ KO mice. Embryonic fibroblasts from PPAR␣ KO and WT mice were transformed with SV40 large T antigen and H-ras, giving rise to two tumorigenic cell lines, PPAR␣ Ϫ/Ϫ MEF/RS and PPAR␣ ϩ/ϩ MEF/RS, respectively (SI Fig. 10 ). Although fenofibrate treatment for 3 days showed 44% dose-dependent inhibition of proliferation of the PPAR␣ Ϫ/Ϫ cells, suggesting off-target effects, the inhibition in the PPAR␣ ϩ/ϩ was significantly higher (P Ͻ 0.02), with a maximal proliferation inhibition of 73% (Fig. 4c) . Thus, whereas PPAR␣ ligands may have PPAR␣-independent antiproliferative effects, pronounced inhibition of cell proliferation requires the presence of the nominal PPAR␣ targets.
The Antitumor Activity of PPAR␣ Ligands Depends on Host PPAR␣ Receptors. Our observations suggest a dual effect of PPAR␣ ligands on both endothelial cells and tumor cells. To evaluate the relative importance of host cells versus tumor cells as targets of PPAR␣ ligands, we treated PPAR␣-positive tumors (PPAR␣ ϩ/ϩ MEF/RS) in PPAR␣ WT and KO mice and PPAR␣-negative tumors (PPAR␣ Ϫ/Ϫ MEF/RS) in PPAR␣ WT mice. The reason we chose the MEF tumor to test the antitumor activity of fenofibrate was that it has shown sufficient growth in the PPAR␣ KO mouse to reveal inhibition by a drug (24) . The MEF tumors grew in the PPAR␣ KO mice mainly because they were transfected with two oncogenes. This gave rise to MEF tumors that were capable of inducing angiogenesis over and above the antiangiogenic state imposed by the PPAR␣ KO mice. In contrast, all other tumors remained viable but dormant and did not grow and therefore were not suitable for testing a drug that inhibits tumor growth.
At the stage when the tumors were 100 mm 3 (corresponding to 9 days postimplantation in PPAR␣ WT mice and 23 days postimplantation in PPAR␣ KO mice), mice were treated with PPAR␣ ligands or vehicle for 16 days. In PPAR␣ WT mice, fenofibrate and WY14643 inhibited the growth of PPAR␣-positive tumors by 90-95% (Fig. 5a ) and of PPAR␣ negative tumors by 75-90% by day 25 postimplantation (Fig. 5b) . The near complete inhibition of tumor growth by PPAR␣ ligands in PPAR␣-positive and PPAR␣-negative tumor cells indicates that PPAR␣ in the tumor cell is not the major target of PPAR␣ ligands. Conversely, in PPAR␣ KO mice, fenofibrate and WY14643 failed to significantly inhibit the growth of PPAR␣ ϩ/ϩ tumors (13% and 33%, respectively; Fig. 5c ) by day 39 postimplantation. Thus, expression of PPAR␣ in the nontumor host tissue is essential for the antitumor activity of PPAR␣ ligands and is sufficient to mediate the antitumor effects of PPAR␣ agonists even if the tumors lack PPAR␣ (Fig. 5d) .
The suppression of tumor growth in the absence of host PPAR␣ has been associated with increased plasma levels of the antiangiogenic protein TSP-1 (24). TSP-1 was not detected in the plasma of WT mice but was present in PPAR␣ KO mice (Fig.  5e) . In WT but not PPAR␣ KO mice, fenofibrate induced high levels of TSP-1, consistent with the strong tumor suppression in WT, ligand-treated animals ( Fig. 5 a and b) . Fenofibrate also induced high levels of endostatin in the plasma of non-tumorbearing PPAR␣ WT mice. Fenofibrate did not have an effect in PPAR␣ KO mice, which already exhibited elevated basal levels of both TSP-1 and endostatin (Fig. 5 e and f ) , indicating that these antiangiogenic effects of fenofibrate were PPAR␣-mediated. In summary, PPAR␣ agonists induced an antiangiogenic state characterized by elevated TSP-1 and endostatin, which is qualitatively similar to the effect of PPAR␣ deficiency.
Discussion
The development of cancer is not simply attributable to the loss of growth control of a single cell clone but rather a developmental disease that involves the tumor cell as well as its interaction with the host tissue. This microenvironment includes endothelial cells, inflammatory cells, and other stromal elements. Therefore, targeting the noncancerous host tissue, mainly by antiangiogenesis mechanisms, has emerged as an important opportunity for tumor therapy (25) . More recently, modulation of tumor-promoting inflammation in the tumor bed has been proposed as a target for cancer treatment (26) .
Here, we report that expression of PPAR␣ in the host tissue is required for PPAR␣ agonists to exert their tumor-suppressing effect. The in vivo antitumor effect was not likely mediated by the in vitro observed direct antitumor cell activity of PPAR␣ agonists, because in PPAR␣ WT animals, the presence of PPAR␣ in the tumor was not necessary to confer responsiveness to PPAR␣ agonists. In summary, animal studies indicate that expression of PPAR␣ in the nontumor host tissue is necessary and sufficient for the tumor-suppressive effect of PPAR␣ agonists. The host tissue contribution may be local (tumor bed) or systemic. Our analysis suggests that this host-mediated effect of PPAR␣ ligands may be attributable to the inhibition of angiogenesis.
Importantly, the doses of the pharmacological PPAR␣ agonists required for tumor inhibition are in the same range as those used clinically to treat hyperlipidemia (22) . PPAR␣ ligands administered at continuous low doses in the diet can suppress tumor and metastatic growth in various experimental tumor models including melanoma, colon, and breast carcinogenesis (11, 27, 28) . However, fenofibrate at daily low doses (25 mg/kg or 0.1-0.25%) lacked antitumor activity in primary hamster melanoma (11) and murine endometrial cancer (9) . This finding is consistent with our observation that 25 mg/kg of fenofibrate had minimal antitumor and antiangiogenic effects (data not shown), whereas 200 mg/kg inhibited angiogenesis and tumor growth.
The antitumor activity of PPAR␣ ligands is primarily PPAR␣-dependent but may also be mediated by PPAR␣-independent (''off-target'') pathways (22) . Here we demonstrated specific PPAR␣-dependent effects of the nominal PPAR␣ ligands: (i) direct activation of the target gene, MCAD, in endothelial cells; (ii) inhibition of tumor and endothelial cell proliferation at doses that selectively activate PPAR␣ in vitro and that were reversed by a PPAR␣ antagonist; and (iii) inhibition of corneal neovascularization in WT but not in PPAR␣ KO mice. Conversely, the presence of PPAR␣-independent activity was evidenced in the moderate inhibition of proliferation of PPAR␣-negative cells. However, this effect may not contribute to in vivo tumor suppression because the antitumor effect of PPAR␣ agonists was mediated by PPAR␣ expressed in the nontumor host tissue.
In addition to the antiproliferative activity, PPAR␣ ligands such as fenofibrate induce a dose-dependent increase in endothelial cell apoptosis and causes arrest in the cell cycle in the G 0 /G 1 phase at higher doses (18) . However, even higher PPAR␣ concentrations also can activate PPAR␥ and/or PPAR␦ (22) . Our studies also show that bezafibrate minimally suppressed the proliferation of endothelial cells yet strongly inhibited corneal neovascularization in vivo. Bezafibrate is a pan-PPAR agonist that activates all three nuclear receptors, PPAR␣, PPAR␥, and PPAR␦ (22) . We and others have found that ligand-induced activation of PPAR␥ inhibits endothelial proliferation and corneal angiogenesis (29) . In contrast, activation of PPAR␦ promotes endothelial proliferation (30) . Thus, one possibility to explain the weak antiendothelial activity of bezafibrate in vitro compared with its robust antiangiogenic activity in vivo is by the relative contribution of each activated PPAR to the overall angiogenic response.
Although our in vitro data revealed a potent role of PPAR␣ ligands in the inhibition of tumor cells, endothelial cell proliferation, and angiogenesis, PPAR␣ ligands also have antiinflammatory effects. The antiinflammatory effect of PPAR␣ ligands is mediated notably through inhibition of inducible NOS, COX-2, and TNF␣ (31) . Inflammatory cells present in the tumor play an important tumor-promoting role (26) by secretion of trophic cytokines for tumor cells as well as proangiogenic factors. Suppression of inflammation in tumors may correlate with improved prognosis and growth inhibition. In agreement with the role of inflammatory cells in tumors and the antiinflammatory activity of PPAR␣ agonists, we show that tumor growth suppression caused by PPAR␣ ligands significantly decreased leukocyte expression within the tumor. Moreover, expression of an inflammatory mediator, COX-2, was decreased in the PPAR␣ ligand-treated tumors.
Although the role of PPAR␣ in inflammation has been well characterized, the modulating effect of PPAR␣ on inflammatory processes in the context of tumor growth remains unclear. We recently reported that PPAR␣ KO mice exhibited a significant increase in inflammatory infiltrates in tumors (24) , consistent with the role of PPAR␣ in the negative modulation of inflammation (2) . However, contrary to the recent notion of inflammation as a tumor promoter (26) , this overt inflammation in PPAR␣ KO mice not only failed to support tumor growth but also appeared to actively suppress it. Specifically, the lack of PPAR␣ resulted in an increase of TSP-1 and endostatin levels in plasma and/or tumors, which may explain the observed tumor suppression.
It is counterintuitive that PPAR␣ activation by agonists and genetic abrogation of PPAR␣ in the host would both lead to tumor inhibition. Treatment of PPAR␣ WT mice with a PPAR␣ agonist led to an increase in TSP-1 and endostatin in tumors and/or plasma, producing an antiangiogenic state similar to the PPAR␣ KO mice (24) . Two perturbations of PPAR␣ activity in opposite directions both inhibit tumor growth and increase TSP-1 and endostatin levels. This underscores the central role of these angiogenesis inhibitors in the control of tumor growth.
Endostatin induces TSP-1 expression (32) . This raises the possibility that these two angiogenesis inhibitors are coordinated.
An analogous paradox of PPAR␣ effect has been described in atherosclerosis. Plaque growth depends on angiogenesis (33) . Atherosclerosis is suppressed not only in PPAR␣ KO mice (34) but also in mice treated with fenofibrate (35) . In more general terms, these counterintuitive results suggest a biphasic (U-shaped) doseresponse curve of host tissue to PPAR␣ activity, as is also observed with PPAR␥ agonists (29) . In other words, very high concentrations or ''very low'' concentrations of PPAR␣ in the host yield the same outcome: maximal suppression of tumor angiogenesis.
Of interest, clinical evidence suggests that long-term administration of fibrates may reduce melanoma progression. Gemfibrozil-treated patients had a 9-fold decrease in melanoma compared with placebo-treated controls, whereas statin-treated patients had a 1.9-fold reduced incidence of melanoma compared with placebo treated controls (36) . Fenofibrate also increased the response rate to retinoids in a human clinical trial for cutaneous T cell lymphoma (37) , suggesting that PPAR␣ ligands may potentiate the effect of other anticancer agents.
In conclusion, we provide a mechanistic rationale for extending the clinical use of the well tolerated PPAR␣ agonists to anticancer therapy, and we show their efficacy in tumor treatment in animal models. The antitumor properties of PPAR␣ ligands appear to be mediated primarily by their direct and indirect antiangiogenic effects and their antiinflammatory activity but also by direct antitumor effects. This provides another example for the paradigm of achieving antitumor efficacy through synergistic attack on multiple targets that encompass cell autonomous and non-cell-autonomous mechanisms of cancer growth. Because of their multifaceted effects and excellent safety and tolerability profile after chronic and prolonged exposure, PPAR␣ ligands may be potential tumor-preventative agents. They may be used for maintenance of long-term angiogenesis suppression. Furthermore, our findings support recent studies (11) (12) (13) (14) that suggest that PPAR␣ ligands may be ideally suited to complement conventional modalities for cancer treatment. Specifically, because fenofilerate is commercially available, it could be evaluated as an extension of existing multidrug regimens, notably in metronomic (antiangiogenic) chemotherapy schemes (38, 39) . However, further research into the pathophysiological role of PPAR␣ and their pharmacological regulators will be paramount to unravel all mechanisms for the antitumor effects of PPAR␣ agonists.
Materials and Methods
Cells and Reagents. Endothelial cells, fibroblasts, and tumor cells were maintained as described (29) in SI Methods. Fenofibrate, bezafibrate, and gemfibrozil were obtained from Sigma; WY14643 and ETYA were from Chem-Syn.
Western Blot Analysis. Western blots were performed by using tumor cell lysates collected from plated cells that were 60% confluent. Total protein extracts (30 g) were analyzed on PVDF membrane blots incubated overnight with rabbit anti-mouse PPAR␣ (Affinity Bioreagents) or rabbit anti-human PPAR␣ (Active Motif). All blots were incubated for 1 h with their corresponding HRP-conjugated secondary antibodies (Amersham Biosciences) and developed with ECL (Pierce). For immunoblotting of TSP and COX-2 (Labvision), the primary antibody was incubated at room temperature for 2 h.
Immunohistochemistry. Sections of tumors were treated with 40 g/ml proteinase K (Roche Diagnostics) for 25 min at 37°C for PECAM1. PECAM1 was amplified by using tyramide signal amplification direct and indirect kits (NEN Life Science Products). CD45 (BD Biosicences) was detected by using a rat-onmouse kit (InnoGenex).
Proliferation Assays. Endothelial, fibroblast, and tumor cell proliferation were assayed as described (29) . For PPAR␣ antagonist studies, MK886 (Alexis Biochemicals) was used. For proliferation of PPAR␣-negative and PPAR␣-positive cells, percentage cell number ϭ 100 ϫ (cells ligand)/(cellsstimluated).
Angiogenesis Assays. Corneal neovascularization assays were performed as described (29) . After implantation of 80 ng of FGF-2 into C57Bl6, PPAR␣ WT, and PPAR␣ KO mice, PPAR␣ ligands were administered over 6 days by gavage in an aqueous solution of 10% DMSO in 0.5% methylcellulose, whereas control mice received vehicle. Tumor cells were injected s.c. (1 ϫ 10 6 cells in 0.1 ml of PBS) into C57BL/6, SCID, PPAR␣ WT, or PPAR␣ KO mice (The Jackson Laboratory). Once tumors reached 100 mm 3 , PPAR␣ ligands were administered by daily gavage for 20 -28 days. Tumor volume was calculated as width squared ϫ length ϫ 0.52. Statistical Analysis. The Student's paired t test was used to analyze the difference between the two groups. Values were considered significant at P Ͻ 0.05.
Note. During the finalization of this article, Pozzi et al. (14) published a report in which they showed PPAR␣-mediated inhibition of angiogenesis and tumor growth. Their findings, although by using a different tumor model and focusing on a single agonist, WY14643, are consistent with ours and confirm the important role of PPAR␣ in tumor suppression.
